… Combination chemotherapy, generally platinum-based plus etoposide or irinotecan, is the
mainstay first-line treatment for metastatic small-cell lung cancer. For non-metastatic disease, …

… The vast majority, more than 95%, of these patients develop small-cell lung cancer because
of tobacco smoking. The risk of developing the cancer increases both with the number of …

… neuroendocrine carcinoma arising predominantly in current or former smokers and has an
exceptionally poor prognosis 1 . SCLC makes up about 15% of lung cancer cases. Patients …

… 20% of lung cancers; most (≈15%) are small cell lung cancer (SCLC). In 2012, an estimated
33,900 new cases of SCLC will occur in the United States. Nearly all cases of SCLC are …

… Small cell lung cancer (SCLC) is an aggressive disease that accounts for approximately
14% of all lung cancers… is illustrated according to percentage in small cell lung cancer (SCLC). …

… Among patients with lung cancers, the proportion of those with small cell lung cancer (SCLC)
has decreased over the last decade. SCLC is staged as limited-stage disease and …

… In 2007, an estimated 213,380 new cases of lung cancer were diagnosed in the United … %
of new cases of lung cancer diagnosed annually and for up to 25% of lung cancer deaths each …

… Microsatellite alterations in 50% of primary small cell lung carcinoma (SCLC) have been …
DNA of cancer patients, we looked for microsatellite alterations in the plasma of SCLC patients. …

… Small cell lung cancer (SCLC) is an aggressive cancer of neuroendocrine origin, which is
strongly associated with cigarette smoking. Patients typically present with a short duration of …

… Topotecan in the treatment of recurrent small cell lung cancer… Topotecan in the treatment
of recurrent small cell lung cancer… for the treatment of recurrent small-cell lung cancer J Clin …